Loading
PRKAA2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming ACLY SiRNA.
In plain words · PRKAA2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
PRKAA2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism.
No product in this corpus aims at PRKAA2 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PRKAA2: RNA tissue enhanced (heart muscle 38 nTPM, skeletal muscle 36 nTPM, tongue 34 nTPM); high antibody staining in 3 normal tissues. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PRKAA2 tissue; Open Targets ENSG00000162409 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Aguan et al, Gene, 1994, "Characterization and chromosomal localization of the human homologue of a rat AMP-activated protein kinase-encoding gene: a major regulator of lipid metabolism in mammals". Source.
Sources: HGNC HGNC:9377 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P54646 (protein name, function text, keywords and locations (REST API)); CIViC gene PRKAA2 (1 evidence items, 0 assertions, 1 variants; diseases: Cancer (GraphQL API, CC0))
Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively. Promotes lipolysis of lipid droplets by mediating phosphorylation of isoform 1 of CHKA (CHKalpha2). Regulates insulin-signalling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3. Location: Cytoplasm; Nucleus; Late endosome (UniProt). Locus 1p32.2 (HGNC).
RNA: tissue enhanced (heart muscle 38 nTPM, skeletal muscle 36 nTPM, tongue 34 nTPM), detected in many normal tissues.
Medium: Cerebellum, Cerebral cortex, Fallopian tube, Testis.
RNA cancer enhanced: Kidney Renal Clear Cell Carcinoma 10 pTPM.
No cancer stained high; medium in breast cancer, carcinoid, colorectal cancer, endometrial cancer.
HPA PRKAA2 tissue · HPA PRKAA2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRKAA2" OR ABSTRACT:"PRKAA2" OR TITLE:"protein kinase AMP-activated catalytic subunit alpha 2" OR ABSTRACT:"protein kinase AMP-activated catalytic subunit alpha 2" OR TITLE:"5'-AMP-activated protein kinase catalytic subunit alpha-2" OR ABSTRACT:"5'-AMP-activated protein kinase catalytic subunit alpha-2" OR TITLE:"AMPKa2" OR ABSTRACT:"AMPKa2" OR TITLE:"PRKAA" OR ABSTRACT:"PRKAA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRKAA2, not a curated reading list.